A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of AZD1613 Following Single and Multiple Dose Administration in Healthy Participants
Latest Information Update: 05 Jun 2025
At a glance
- Drugs AZD 1613 (Primary) ; AZD 1613 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 05 Jun 2025 New trial record